Endocrine Society Calls on Congress to Address High Insulin Prices and Consumer Out-of-Pocket Costs

President Biden cites need for affordable diabetes care in State of the Union.

The Endocrine Society praised President Biden for affirming his commitment to improving insulin affordability during the State of the Union address.
 

We cannot lose sight of this ongoing crisis, which continues to impact millions of Americans living with diabetes. The Administration must work with Congress to find a meaningful solution. The Society urges Congress to pass legislation on a bipartisan basis to make insulin more affordable for those who rely on it.

The millions of people living with diabetes for whom insulin is a lifesaving medication cannot wait. Insulin has nearly tripled in price over the last 15 years, making it unaffordable for many.

More than 37 million people nationwide—11.3% of the total population—have diabetes. Recent data found that 3.1 million adults started using insulin within a year of being diagnosed with diabetes. While other medications offer options for individuals with type 2 diabetes, those with type 1 diabetes must take insulin daily for the rest of their lives.

Our position statement recommends an array of different policy options, many of which Congress should  pass today, to lower the price and consumer out-of-pocket costs of insulin.

Members of Congress from both political parties have acknowledged access to affordable insulin is a problem. Rising costs have increased health disparities in the country and have particularly jeopardized the health of minorities, low-income individuals, people on high-deductible health plans, Medicare beneficiaries, and those who must transition from their parents’ insurance after turning 26.

Numerous bipartisan investigations and hearings have concluded that insulin is unaffordable for many people living with diabetes. Despite this acknowledgement, legislation has stalled in the Senate and both chambers still must agree on policy to advance to the president.

We commend the bipartisan work that has been done by the House Energy & Commerce Committee, the Senate Finance Committee, the Congressional Diabetes Caucus, and many other committees and caucuses to shed light on this issue.

We urge Congress to come together and pass legislation to make insulin affordable as soon as possible. This legislation must address the drivers of rising insulin prices and implement solutions that will lower the out-of-pocket costs for patients.

You may also like

  • Hammer Wins Inaugural Endocrine Images Art Competition

    Gary Hammer, MD, PhD, Millie Schembechler professor of Adrenal Cancer at the University of Michigan in Ann Arbor, Mich., won the Endocrine Society’s Endocrine Images Art Competition, a contest celebrating the beauty of endocrine science. Entries were judged based on aesthetic value and significance to endocrine research. Hammer’s image of the adrenal gland took the top…

  • Endocrine Society’s Insulin 2121 Event Kickstarts Diabetes Awareness Month

    Throughout 2021, the Endocrine Society has focused on insulin’s past and present. The Society’s Insulin 2121 event highlights insulin’s future. Robots, drones, and artificial intelligence are just a few of the innovative topics being discussed. While the event is pre-recorded, our speakers will be live and available to answer your questions in real time during the Q&A portion.   More information on the…

Find more in